US2013324532A1PendingUtilityA1
Fak inhibitors
Est. expiryFeb 17, 2031(~4.6 yrs left)· nominal 20-yr term from priority
Inventors:Ian HolmesYiva BergmanGillian Elizabeth LunnissMarcia NikacNeil ChoiCatherine Fae HemleyScott Raymond WalkerRichard Charles FoitzikDanny GanameRomina Lessene
C07D 401/12A61P 35/02C07D 403/14A61K 31/506C07D 413/12A61K 39/3955C07D 403/12C07D 401/14C07D 239/42A61P 35/00C07D 403/06A61K 39/395A61P 43/00
52
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A compound of the formula (I): where R 1 or R 2 is a cyclc amine group and R 5 is an aromatic group with a carbonyl containing substituent for use as a FAK inhibitor.
Claims
exact text as granted — not AI-modified1 . A compound of the formula (I):
wherein:
R 1 is selected from: H and
wherein:
R N1 is selected from H, C 1-3 alkyl and C(═O)Me;
R N2 is selected from H, C 1-3 alkyl and C(═O)Me;
R N3 is selected from H, C 1-3 alkyl and C(═O)Me;
R N4 is selected from H and CH 3 ;
R N7 and R N8 are independently selected from H and CH 3 ;
R N9 is selected from H, C 1-3 alkyl and C(═O)Me;
R N10 is selected from H, C 1-3 alkyl and C(═O)Me;
R N11 is selected from H, C 1-3 alkyl and C(═O)Me;
R 2 is selected from H and
wherein:
R N5 is selected from H, C 1-3 alkyl and C(═O)Me;
R N6 is selected from H, C 1-3 alkyl and C(═O)Me;
and wherein only one of R 1 and R 2 is H;
or R 1 and R 2 together form the group —CH—N(R N12 )—C 2 H 4 —, where R N12 is selected from H, C 1-3 alkyl and C(═O)Me;
R 4 is selected from CF 3 , halo, CF 2 H and CN; and
R 5 is selected from groups of the following formulae:
wherein:
R 6 is selected from H, (CHR C1 ) n1 C(O)N(R N6 )Z 1 and (CH 2 ) 2 C(O)OZ 2 ; wherein:
n1 is 1;
R C1 is H or Me;
R N12 is H or CH 3 ;
Z 1 is H, CH 3 or OCH 3 ;
n2 is 1; and
Z 2 is CH 3 ;
and where only one of R N12 and Z 1 can be CH 3 ,
R 7 , if present, is selected from H, and (CH 2 ) m1 C(O)N(R M1 )Y 1 , wherein:
m1 is 0 or 1;
R M1 is H; and
Y 1 is H, Me or OCH 3 ;
and one of R 6 and R 7 is not H; and
R 8 , if present, is H or, when R 7 is C(═O)NH 2 , R 8 is selected from H and C 1-2 alkyl.
2 . A compound according to claim 1 , wherein R 2 is H and R 1 is selected from the group consisting of:
(a),
wherein R N1 is C(═O)Me;
(b)
wherein R N1 is H, methyl or ethyl:
(c)
wherein R N2 is selected from H methyl and ethyl;
(d)
wherein R N3 is selected from H and methyl;
(e)
wherein R N4 selected from H and methyl;
(f)
wherein R N7 and R N8 are both H or both methyl;
(g)
wherein R N9 is H;
(h)
wherein R N10 is selected from H and methyl; and
(i)
wherein R N11 is H.
3 - 10 . (canceled)
11 . A compound according to claim 1 , wherein R 1 is H and R 2 is selected from the group consisting of:
(a)
where R N5 is selected from H and methyl; and
(b)
where R N6 is selected from H and methyl.
12 . (canceled)
13 . A compound according to claim 1 , wherein R 4 is selected from CF 3 , Cl and CF 2 H.
14 . A compound according to claim 13 , wherein R 4 is CF 3 .
15 . A compound according to claim 1 , wherein R 5 is a group of the following formula:
16 . A compound according to claim 1 , wherein R 5 is a group selected from:
17 . A compound according to claim 15 , wherein R 7 is H and R 6 is selected from CH 2 C(O)NH 2 , CH 2 C(O)NHCH 3 , CHCH 3 C(O)NH 2 and CHCH 3 C(O)NHCH 3 .
18 . A compound according to claim 17 , wherein R 7 is H and R 6 is selected from CH 2 C(O)NH 2 , CHCH 3 C(O)NH 2 and CH 2 C(O)NHCH 3 .
19 . A compound according to claim 18 , wherein R 7 is H and R 6 is selected from CH 2 C(O)NH 2 , and CHCH 3 C(O)NH 2 .
20 . A compound according to claim 15 , wherein R 6 is H and R 7 is selected from C(O)NH 2 , C(O)NHCH 3 , CH 2 C(O)NH 2 and CH 2 C(O)NHCH 3 .
21 . A compound according to claim 20 , wherein R 6 is H and R 7 is C(O)NH 2 .
22 . A compound according to claim 21 , wherein R 8 is methyl.
23 . A compound according to claim 1 , wherein R 5 is a group of the following formula:
24 . A composition comprising a compound according to claim 1 , and a pharmaceutically acceptable carrier or diluent.
25 - 28 . (canceled)
29 . A method of inhibiting FAK in vitro or in vivo, comprising contacting a cell with an effective amount of a compound according to claim 1 .
30 . A method of treating a disease ameliorated by the inhibition of FAK comprising administering a compound according to claim 1 .
31 . A method of treating a disease ameliorated by the inhibition of FAK comprising administering a composition according to claim 24 .
32 . A compound according to claim 16 , wherein R 7 is H and R 6 is selected from CH 2 C(O)NH 2 , CH 2 C(O)NHCH 3 , CHCH 3 C(O)NH 2 and CHCH 3 C(O)NHCH 3 .
33 . A compound according to claim 16 , wherein R 6 is H and R 7 is selected from C(O)NH 2 , C(O)NHCH 3 , CH 2 C(O)NH 2 and CH 2 C(O)NHCH 3 .Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.